Aurobindo Pharma Ltd.

BSE: AUROPHARMA524804ISIN INE406A01037

Healthcare
Pharmaceuticals
BSE 200

BSE listing

Share price

₹1,735.00+51.05 (+3.03%)

as of 18 Sep 2026

52W high: ₹1,735.00
52W low: ₹1,066.00
Off 52W high: 0.00%
1M return: +7.42%
3M return: +15.83%
6M return: +34.35%
1Y return: +53.74%
20D avg volume: 20,560
50 DMA: ₹1,616.29
200 DMA: ₹1,392.51

Key ratios Consolidated

Market cap: ₹99,828 Cr
Current price: ₹1,735.00
52W high / low: ₹1,735.00 / ₹1,066.00
Face value: ₹1.00
P/E: 26.90
P/B: —
EPS (TTM): ₹64.49
Book value / share: —
ROE: —
ROCE: 13.60%
Operating margin: —
Net margin: —
Debt / equity: 0.20
Net debt: ₹484.80 Cr
Interest cover: 14.31
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 147.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	9,150	8,853	8,646	8,286	7,868	8,382	7,979	7,796	7,567	7,580	7,352	7,219
	264.23	117.04	187.64	120.59	105.30	134.81	157.29	136.00	220.93	135.62	162.52	186.98
	7,858	7,677	7,430	7,132	6,769	7,150	6,938	6,725	6,463	6,351	6,249	6,332
	2,894	2,505	2,755	2,510	2,535	2,800	2,729	2,742	2,467	2,635	2,676	2,709
	931.78	931.48	892.65	846.05	807.80	636.18	823.89	747.03	680.01	785.95	775.75	631.07
	1,480	1,374	1,310	1,277	1,229	1,163	1,132	1,109	1,072	1,026	989.68	954.97
	101.66	98.21	92.77	95.24	97.75	115.02	118.48	112.70	111.04	89.43	75.55	68.18
	486.82	478.57	464.73	429.19	405.70	444.43	418.53	382.28	404.18	354.33	423.27	417.50
	2,162	2,298	2,081	1,991	1,797	2,000	1,904	1,910	1,803	1,806	1,610	1,624
	1,557	1,293	1,403	1,274	1,205	1,367	1,198	1,207	1,325	1,365	1,265	1,075
	-40.18	0.00	-65.33	0.00	0.00	0.00	0.00	0.00	0.00	-122.11	0.00	0.00
	1,517	1,293	1,338	1,274	1,205	1,367	1,198	1,207	1,325	1,243	1,265	1,075
	483.06	369.77	428.72	427.79	382.60	432.26	354.28	390.51	405.67	322.55	322.45	323.70
	1,032	920.84	909.80	848.13	824.20	902.83	845.57	816.95	918.22	907.35	939.97	751.94
	17.86	15.86	15.67	14.61	14.20	15.56	14.56	14.00	15.69	15.51	16.04	12.83
Key metrics
	2,105	1,870	1,896	1,799	1,708	1,927	1,735	1,702	1,840	1,686	1,764	1,560
	23.00%	21.10%	21.90%	21.70%	21.70%	23.00%	21.70%	21.80%	24.30%	22.20%	24.00%	21.60%
	11.30%	10.40%	10.50%	10.20%	10.50%	10.80%	10.60%	10.50%	12.10%	12.00%	12.80%	10.40%
	—	3.40%	—	3.70%	—	4.20%	—	—	—	—	—	—
	16.30%	5.60%	8.40%	6.30%	4.00%	10.60%	8.50%	8.00%	—	—	—	—
	25.20%	2.00%	7.60%	3.80%	-10.20%	-0.50%	-10.00%	8.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	34,935	33,653	31,724	29,002	24,855	23,455	24,775	23,098	19,564	16,500
	689.50	492.09	621.85	557.38	290.59	320.35	380.84	86.20	115.66	101.98
	30,097	28,970	27,248	24,970	22,522	20,244	20,571	19,400	16,502	13,364
	10,664	10,305	10,737	10,776	9,653	7,372	8,317	7,725	7,445	5,629
	3,602	3,478	2,887	2,773	2,050	1,952	2,315	2,112	1,943	1,606
	5,442	5,190	4,476	3,923	3,522	3,451	3,535	3,219	2,585	2,131
	387.88	383.97	457.24	289.71	140.48	48.64	74.49	159.77	162.66	77.71
	1,859	1,778	1,649	1,522	1,245	1,127	1,055	966.71	667.95	—
	8,532	8,129	7,639	6,633	6,282	5,478	6,004	5,280	4,314	3,828
	5,528	5,176	5,098	4,589	2,624	3,532	4,584	3,784	3,177	3,238
	-105.51	-65.33	0.00	-191.86	0.00	-127.97	2,815	-26.13	-88.06	3.14
	5,422	5,110	5,098	4,397	2,624	3,404	7,399	3,758	3,089	3,241
	1,709	1,609	1,583	1,211	684.85	725.63	2,010	913.51	726.85	818.28
	3,711	3,503	3,484	3,169	1,928	2,647	5,334	2,830	2,364	2,423
	64.00	60.34	59.81	54.16	32.90	45.19	91.04	48.32	40.36	—
Key metrics
	7,669	7,272	7,205	6,209	4,009	4,579	8,529	4,885	3,919	3,319
	21.95%	21.60%	22.70%	21.40%	16.10%	19.50%	34.40%	21.10%	20.00%	20.10%
	10.62%	10.40%	11.00%	10.90%	7.80%	11.30%	21.50%	12.20%	12.10%	14.70%
	—	13.60%	15.80%	—	—	—	—	—	—	—
	—	6.10%	9.40%	16.70%	6.00%	-5.30%	7.30%	18.10%	18.60%	—
	—	0.60%	9.90%	64.40%	-27.20%	-50.40%	88.50%	19.70%	-2.40%	—
	—	2,841	1,957	—	—	—	—	—	—	—
	—	1.58	1.13	—	—	—	—	—	—	—
	—	0.20	0.24	—	—	—	—	—	—	—
	—	484.80	2,373	—	—	—	—	—	—	—
	—	147.2	139.2	—	—	—	—	—	—	—
Balance sheet
	—	58,502	49,785	—	—	—	—	—	—	—
	—	32,709	27,162	—	—	—	—	—	—	—
	—	7,191	5,569	—	—	—	—	—	—	—
	—	7,094	5,746	—	—	—	—	—	—	—
	—	12,053	10,544	—	—	—	—	—	—	—
	—	2,803	2,357	—	—	—	—	—	—	—
	—	14,330	12,189	—	—	—	—	—	—	—
	—	5,567	4,189	—	—	—	—	—	—	—
	—	18,039	14,682	—	—	—	—	—	—	—
	—	7,676	7,942	—	—	—	—	—	—	—
	—	6,873	6,380	—	—	—	—	—	—	—
	—	802.75	1,562	—	—	—	—	—	—	—
	—	37,883	32,647	—	—	—	—	—	—	—
Cash flow
	—	5,526	3,925	—	—	—	—	—	—	—
	—	-3,458	-1,875	—	—	—	—	—	—	—
	—	-1,269	119.78	—	—	—	—	—	—	—
	—	2,686	1,968	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,800	2,787	2,747	2,790	2,848	2,732	2,917	2,825	2,460	2,894	2,692	2,669
	241.89	214.09	130.15	159.52	83.77	113.98	54.26	122.66	65.32	122.97	331.13	67.08
	2,033	2,124	2,078	2,194	2,182	2,290	2,338	2,224	2,079	2,237	2,336	2,226
	1,289	1,252	1,403	1,244	1,340	1,361	1,507	1,425	1,318	1,402	1,466	1,518
	0.00	16.52	20.15	22.15	14.38	16.31	19.06	16.16	13.60	17.01	155.09	15.77
	295.91	292.71	291.10	294.37	282.97	273.11	265.15	265.48	259.33	248.91	248.08	247.51
	47.07	47.27	48.43	57.45	60.00	61.09	66.19	51.63	51.13	53.07	61.25	36.69
	68.99	71.93	71.92	71.49	70.02	93.88	68.28	68.16	66.88	64.81	64.35	65.79
	380.51	401.45	379.99	403.07	375.99	424.84	445.95	428.58	405.61	464.86	401.00	369.09
	1,008	876.31	799.28	755.28	750.09	555.52	632.94	723.75	446.24	779.88	687.22	509.78
	0.00	0.00	-17.38	0.00	0.00	0.00	—	—	—	—	—	—
	1,008	876.31	781.90	755.28	750.09	555.52	632.94	723.75	446.24	779.88	687.22	509.78
	270.86	184.08	199.83	173.91	190.96	147.35	160.89	186.22	117.20	201.21	63.44	130.13
	737.22	692.23	582.07	581.37	559.13	408.17	472.05	537.53	329.04	578.67	623.78	415.74
	12.75	11.92	10.02	10.01	9.63	7.03	8.13	9.21	5.62	9.88	10.65	6.48
Key metrics
	1,124	995.51	902.25	884.22	880.11	710.49	767.41	843.54	564.25	897.76	812.82	612.26
	40.20%	35.70%	32.80%	31.70%	30.90%	26.00%	26.30%	29.90%	22.90%	31.00%	30.20%	22.90%
	26.30%	24.80%	21.20%	20.80%	19.60%	14.90%	16.20%	19.00%	13.40%	20.00%	23.20%	15.60%
	—	4.00%	—	3.70%	—	2.90%	—	—	—	—	—	—
	-1.70%	2.00%	-5.80%	-1.20%	15.80%	-5.60%	8.30%	5.80%	—	—	—	—
	31.90%	69.60%	23.30%	8.20%	69.90%	-29.50%	-24.30%	29.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	11,123	11,172	10,933	10,646	12,792	11,287	15,824	13,266	12,258	10,303
	745.65	587.53	328.12	616.06	433.76	670.99	589.86	258.01	109.60	80.65
	8,430	8,578	8,903	8,859	11,612	10,246	12,221	11,147	10,403	8,041
	5,187	5,238	5,610	5,761	7,248	5,784	7,216	6,748	6,455	4,893
	58.82	73.20	65.13	203.40	89.23	16.81	26.09	5.51	14.25	3.72
	1,174	1,161	1,063	980.56	1,642	1,600	1,735	1,561	1,363	1,132
	200.22	213.15	230.04	182.60	114.98	16.94	28.68	95.58	130.92	52.89
	284.33	285.36	297.20	254.58	435.35	415.26	487.99	470.48	413.03	354.83
	1,565	1,560	1,705	1,593	2,549	2,367	2,724	2,496	2,306	1,939
	3,439	3,181	2,358	2,403	1,614	1,712	4,193	2,378	1,965	2,343
	-17.38	-17.38	0.00	—	—	-74.71	—	—	—	—
	3,422	3,164	2,358	2,403	1,614	1,637	4,193	2,378	1,965	2,343
	828.68	748.78	611.66	502.82	383.94	182.77	1,080	504.96	434.89	530.17
	2,593	2,415	1,747	1,954	1,230	1,455	3,113	1,873	1,530	1,813
	44.70	41.58	29.97	32.43	21.00	24.83	53.13	31.96	26.11	—
Key metrics
	3,906	3,662	2,886	2,840	2,165	2,070	4,710	2,944	2,509	2,751
	35.12%	32.80%	26.40%	26.70%	16.90%	18.30%	29.80%	22.20%	20.50%	26.70%
	23.31%	21.60%	16.00%	18.40%	9.60%	12.90%	19.70%	14.10%	12.50%	17.60%
	—	14.70%	12.30%	—	—	—	—	—	—	—
	—	2.20%	2.70%	-16.80%	13.30%	-28.70%	19.30%	8.20%	19.00%	—
	—	38.20%	-10.60%	58.80%	-15.40%	-53.30%	66.20%	22.40%	-15.60%	—
	—	2,412	1,399	—	—	—	—	—	—	—
	—	1.21	0.94	—	—	—	—	—	—	—
	—	0.18	0.23	—	—	—	—	—	—	—
	—	4,022	4,330	—	—	—	—	—	—	—
	—	154.7	159.1	—	—	—	—	—	—	—
Balance sheet
	—	29,279	27,513	—	—	—	—	—	—	—
	—	8,022	7,689	—	—	—	—	—	—	—
	—	160.43	295.26	—	—	—	—	—	—	—
	—	4,210	4,195	—	—	—	—	—	—	—
	—	2,361	2,359	—	—	—	—	—	—	—
	—	554.01	624.99	—	—	—	—	—	—	—
	—	2,420	2,185	—	—	—	—	—	—	—
	—	1,832	1,787	—	—	—	—	—	—	—
	—	6,299	6,420	—	—	—	—	—	—	—
	—	4,182	4,625	—	—	—	—	—	—	—
	—	4,182	4,225	—	—	—	—	—	—	—
	—	0.00	400.00	—	—	—	—	—	—	—
	—	22,718	20,534	—	—	—	—	—	—	—
Cash flow
	—	2,933	1,646	—	—	—	—	—	—	—
	—	-2,025	-2,066	—	—	—	—	—	—	—
	—	-1,072	616.31	—	—	—	—	—	—	—
	—	520.61	246.94	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -4.41%
Sales CAGR 5Y: -6.73%
Sales CAGR 10Y: —
Profit CAGR 3Y: +25.20%
Profit CAGR 5Y: -4.95%
Profit CAGR 10Y: —
Sales YoY (TTM): -1.75%
Profit YoY (TTM): +31.16%

Consolidated

Sales CAGR 3Y: +10.63%
Sales CAGR 5Y: +6.32%
Sales CAGR 10Y: —
Profit CAGR 3Y: +22.03%
Profit CAGR 5Y: -8.07%
Profit CAGR 10Y: —
Sales YoY (TTM): +9.09%
Profit YoY (TTM): +9.48%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 51.87%

Holder	Type	Holding	Previous	Change
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING)	Promoter Group	33.54%	—	—
QUANT MUTUAL FUND	Public	4.96%	—	—
KAMBAM NITHYANANDA REDDY	Promoter	4.37%	—	—
SBI LARGE & MIDCAP FUND	Public	3.57%	—	—
KIRTHI REDDY KAMBAM	Promoter Group	3.46%	—	—
HDFC MUTUAL FUND	Public	3.22%	—	—
VENKATA RAMPRASAD REDDY PENAKA	Promoter	3.07%	—	—
LIFE INSURANCE CORPORATION OF INDIA	Public	2.94%	—	—
AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING)	Promoter Group	2.86%	—	—
NPS TRUST - A/C SBI PENSION FUND SCHEME - NPS TIER	Public	2.74%	—	—
M SIVAKUMARAN	Promoter Group	2.48%	—	—
KAMBAM SPOORTHI	Promoter Group	1.20%	—	—
KOTTAMANCHI RAJESWARI	Promoter Group	0.31%	—	—
M SUMANTH KUMAR REDDY	Promoter Group	0.27%	—	—
TRIDENT CHEMPHAR LIMITED	Promoter Group	0.13%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.15 Sep 2026 · Company Update / General
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.15 Sep 2026 · Company Update / Press Release / Media Release
Intimation of subscription of 10,000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company.12 Sep 2026 · Company Update / Acquisition
Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.11 Sep 2026 · Company Update / General
Intimation of investor / analyst meet scheduled on 22.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of investor / analyst meet scheduled on 21.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of investor / analyst meet scheduled on 17.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of investor / analyst meet scheduled on 18.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of Investor / analyst meet scheduled on 17.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Submission of notice published in newspapers.3 Sep 2026 · Company Update / Newspaper Publication
Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited'' by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.1 Sep 2026 · Company Update / Acquisition
Submission of Press Release.31 Aug 2026 · Company Update / Press Release / Media Release (Revised)
Intimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.28 Aug 2026 · Company Update / General
Submission of Voting Results and Scrutinizer''s Report of 39th AGM of the Company held on August 27, 2026.28 Aug 2026 · AGM/EGM / AGM
Submission of proceedings of 39th Annual General Meeting of the Company held on 27th August, 2026.27 Aug 2026 · AGM/EGM / AGM
Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong25 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of Investor/ Analyst meet scheduled on September 1, 2026.25 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.24 Aug 2026 · Company Update / General
Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.21 Aug 2026 · Company Update / General
Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).17 Aug 2026 · Company Update / General
Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 202614 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.14 Aug 2026 · Company Update / General
Submission of transcript of the earning call on the unaudited financial results for the quarter ended June 30, 2026.13 Aug 2026 · Company Update / Earnings Call Transcript
Intimation of incorporation of a new wholly owned subsidiary.13 Aug 2026 · Company Update / Acquisition
Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.7 Aug 2026 · Company Update / Newspaper Publication
Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on ....7 Aug 2026 · Company Update / Newspaper Publication
Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong Kong6 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.5 Aug 2026 · Company Update / Restructuring
Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.5 Aug 2026 · Company Update / Press Release / Media Release
Submission of investor presentation.5 Aug 2026 · Company Update / Investor Presentation
The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results ....5 Aug 2026 · Board Meeting / Outcome of Board Meeting
Submission of copies of notice published in newspapers.4 Aug 2026 · Company Update / Newspaper Publication
Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.4 Aug 2026 · Company Update / General
Submission of BRSR for FY 2025-26.3 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Submission of Notice of 39th Annual General Meeting of the Company to be held August 27, 2026.3 Aug 2026 · AGM/EGM / AGM
Submission of Integrated Annual Report 2025-263 Aug 2026 · Others / Reg. 34 (1) Annual Report
Submission of copies of notice published in newspapers intimating the shareholders that the 39th AGM of the Company will be held on August 27, 2026.30 Jul 2026 · Company Update / Newspaper Publication
Intimation of 39th Annual General Meeting of Aurobindo Pharma Limited to be held on August 27, 2026.29 Jul 2026 · AGM/EGM / AGM
Intimation of schedule of Earnings Call to be held on August 6, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.29 Jul 2026 · Company Update / Analyst / Investor Meet
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....27 Jul 2026 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Buy Back of Shares	17 Apr 2026	17 Apr 2026	—
Interim Dividend - Rs. - 4.0000	8 Aug 2025	8 Aug 2025	—
Buy Back of Shares	30 Jul 2024	30 Jul 2024	—

Board meetings

5 Aug 2026 Board Meeting - Financial Results